



# ASK THE EXPERT™

## First-Line Treatment of Metastatic Non-small cell Lung Cancer

Use of first-line (1L) OPDIVO® (nivolumab) in combination with low-dose YERVOY® (ipilimumab) in certain patients with metastatic NSCLC with PD-L1 expression  $\geq 1\%$

### FACULTY



**Martin Dietrich, MD, PhD**  
Medical Oncologist  
Florida Cancer Specialists  
& Research Institute  
Orlando, FL

Dr Dietrich was paid to share his perspective in this interview. He has also served as a clinical investigator and a scientific advisor for Bristol-Myers Squibb Company.

Please see end for additional industry-related disclosures.

### INTRODUCTION

According to the American Cancer Society, it is estimated that approximately 228,820 new cases of lung cancer were diagnosed in the United States in 2020, that will result in about 135,720 deaths.<sup>1,2</sup> In the US, non-small cell lung cancer (NSCLC) comprises 80% to 85% of these lung cancer cases.<sup>2</sup>

Recent advances in the treatment of metastatic NSCLC, with the advent of immune-oncology (I-O) products, have led to improvements in clinical outcomes. The emergence of I-O therapies, used alone or in combination with chemotherapy, has enhanced the treatment paradigm in NSCLC.

Companies have been researching new I-O treatments and approaches to first-line (1L) treatment of NSCLC, including combination treatments for NSCLC with no targetable driver mutation. Nivolumab, in combination with ipilimumab, is approved by the US Food and Drug Administration (FDA) for the 1L treatment for adult patients with metastatic NSCLC whose tumors express PD-L1 ( $\geq 1\%$ ) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor alterations.<sup>3</sup>

### INDICATIONS

#### For Patients With Metastatic Non-Small Cell Lung Cancer

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 ( $\geq 1\%$ ) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDIVO, in combination with YERVOY and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

**Please see Select Important Safety Information on page 14. Please see Brief Summary of Full Prescribing Information on pages 15 through 19.**

## ► INTERVIEW WITH DR DIETRICH

**Q: What is the scientific rationale for inhibition of PD-1 plus CTLA-4 with OPDIVO + YERVOY as a 1L treatment in PD-L1  $\geq$ 1% mNSCLC?**

**A:** OPDIVO + YERVOY is a unique combination of 2 immune checkpoint inhibitors that work in different but complementary ways. The potentially synergistic mechanisms help destroy tumor cells and make it possible to deliver an enhanced anti-tumor response greater than the effects of either antibody alone.

- OPDIVO helps existing T cells discover the tumor by blocking the immune checkpoint PD-1.<sup>4</sup>
- YERVOY helps activate and proliferate cytotoxic T cells by blocking the immune checkpoint CTLA-4 and also reduces Treg function.<sup>5-11</sup>
- Targeting of normal cells can also occur and result in immune-mediated adverse reactions, which can be severe and potentially fatal.<sup>4,5</sup>

## IMPORTANT SAFETY INFORMATION

### Severe and Fatal Immune-Mediated Adverse Reactions


Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

**Please see Select Important Safety Information on page 14. Please see Brief Summary of Full Prescribing Information on pages 15 through 19.**

Checkmate 227 was a landmark, open-label, phase 3 trial in which Part 1a evaluated OPDIVO + YERVOY compared to platinum-based chemotherapy as 1L therapy in patients with stage IV or recurrent NSCLC, regardless of histology, no known sensitizing *EGFR* or *ALK* alterations, and PD-L1 expression  $\geq 1\%$  (**see Figure 1**).<sup>12-15</sup> In an extended overall survival (OS) analysis for Checkmate 227, median follow-up was 43.1 months – one of the longest follow-ups of any approved dual I-O in a phase 3 trial.<sup>15</sup> In Checkmate 227, 29% of patients enrolled had squamous disease and 71% had non-squamous disease.



\*In Checkmate 227, patients in the comparator arm received up to 4 cycles of platinum-doublet chemotherapy every 3 weeks; nonsquamous (NSQ) NSCLC: pemetrexed plus carboplatin or cisplatin, with optional pemetrexed maintenance following chemotherapy; squamous (SQ) NSCLC: gemcitabine plus carboplatin or cisplatin.<sup>4,13,14</sup>

- Patients with untreated brain metastases, carcinomatous meningitis, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded.
- Tumor specimens were evaluated prospectively using the PD-L1 IHC 28-8 pharmDx assay at a central laboratory.

## IMPORTANT SAFETY INFORMATION

### Severe and Fatal Immune-Mediated Adverse Reactions

#### Immune-Mediated Pneumonitis

OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In NSCLC patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, immune-mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.

**Q:** In Checkmate 227 Part 1a, 1L OPDIVO + YERVOY demonstrated durable, long-term OS versus chemotherapy in patients with PD-L1  $\geq 1\%$  mNSCLC. We have now seen data with a median follow-up of more than 3 years (43.1 months). What is the clinical significance of these data?

**A:** In Checkmate 227 Part 1a, PFS, ORR, and duration of response (DOR) were pre-specified descriptive analyses. The primary efficacy outcome measure was OS.<sup>4,14</sup> Among the patients with PD-L1 expression  $\geq 1\%$ , at the primary analysis (minimum follow-up of 29.3 months) the median OS was 17.1 months (95% confidence interval [CI], 15.0-20.1) with OPDIVO + YERVOY and 14.9 months (95% CI, 12.7-16.7) with chemotherapy ( $P=.007$ ). Median PFS was 5.1 months (95% CI, 4.1-6.3) with OPDIVO + YERVOY and 5.6 months (95% CI, 4.6-5.8) with chemotherapy alone (HR=0.82; 95% CI, 0.69-0.97).<sup>4</sup>

With a median follow-up of 43.1 months, 33% of patients treated with OPDIVO + YERVOY were alive at 3 years and 22% of patients treated with chemotherapy were alive.<sup>14</sup> These descriptive landmark analyses showed that OPDIVO + YERVOY offers patients dual I-O durability and long-term survival.

## IMPORTANT SAFETY INFORMATION

### Severe and Fatal Immune-Mediated Adverse Reactions

#### Immune-Mediated Colitis


OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

#### Immune-Mediated Hepatitis and Hepatotoxicity

OPDIVO and YERVOY can cause immune-mediated hepatitis.

**Please see Select Important Safety Information on page 14. Please see Brief Summary of Full Prescribing Information on pages 15 through 19.**

Figure 2. Overall survival (extended follow-up analysis in patients with PD-L1  $\geq 1\%$ )



## IMPORTANT SAFETY INFORMATION

### Severe and Fatal Immune-Mediated Adverse Reactions

#### Immune-Mediated Endocrinopathies

OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.

#### Immune-Mediated Nephritis with Renal Dysfunction

OPDIVO and YERVOY can cause immune-mediated nephritis.

**Q:** Can you explain the post-hoc exploratory analysis in which OS in responders was assessed and the clinical relevance of that data?

**A:** This is an interesting question. This is a look at the patient population that maintained a positive response (complete response/partial response [CR/PR]) at 6 months. At 1, 2, and 3 years post-landmark where 90%, 76%, and 70%, respectively, of those treated with OPDIVO + YERVOY who had responded at 6 months were still alive.

This was a post-hoc, exploratory, conditional landmark analysis where patients were grouped by response category based on assessment at 6 months.

- A conditional landmark analysis can minimize potential guarantee time bias when the time to response may be different between arms or when comparing responding patients and non-responding patients
- No formal statistical testing was planned for this and, therefore, no statistical conclusions can be drawn
- The 6-month time point was chosen because it is the earliest time point when most of the responses in each treatment arm had occurred
- An important limitation of this analysis is that responding patients who died before 6 months were not included

### IMPORTANT SAFETY INFORMATION

#### Severe and Fatal Immune-Mediated Adverse Reactions

#### Immune-Mediated Dermatologic Adverse Reactions


OPDIVO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes.

YERVOY can cause immune-mediated rash or dermatitis, including bullous and exfoliative dermatitis, SJS, TEN, and DRESS. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes.

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).

**Please see Select Important Safety Information on page 14. Please see Brief Summary of Full Prescribing Information on pages 15 through 19.**

**Figure 3. Overall survival in responders (CR/PR) at 6 months (post-hoc exploratory analysis in patients with PD-L1 ≥1%)**



Minimum follow-up for post-landmark OS: 31.7 months.

Post-randomization: Time point measurement starting from treatment initiation (month 0).

NR indicates not reached; CR, complete response; PR, partial response.

## IMPORTANT SAFETY INFORMATION

### Severe and Fatal Immune-Mediated Adverse Reactions

#### Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received OPDIVO monotherapy or OPDIVO in combination with YERVOY or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions: cardiac/vascular: myocarditis, pericarditis, vasculitis; nervous system: meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; ocular: uveitis, iritis, and other ocular inflammatory toxicities can occur; gastrointestinal: pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis; musculoskeletal and connective tissue: myositis/polymyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica; endocrine: hypoparathyroidism; other (hematologic/immune): hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.

**Q:** In Checkmate 227 Part 1a, the median DOR was 23.2 months for OPDIVO + YERVOY. What is the clinical relevance of this data?

**A:** At a minimum follow-up of 29.3 months, the overall response rate (ORR) was 36% (142/396, 95% CI, 31-41), with CR=5.8% and PR=30.1% with OPDIVO + YERVOY and 30% (119/397, 95% CI, 26-35), CR=1.8%, PR=28.2% with chemotherapy.

At a median follow-up of 43.1 months, the median DOR in the 3-year follow-up analysis of Checkmate 227 was 23.2 months among OPDIVO + YERVOY responders and 6.7 months among chemotherapy responders. Of patients treated with OPDIVO + YERVOY, 64%, 49%, and 38% remained in response at 12, 24, and 36 months, respectively, and 29%, 12%, and 4% at these time points for patients treated with chemotherapy.

### IMPORTANT SAFETY INFORMATION


#### Other Immune-Mediated Adverse Reactions

In addition to the immune-mediated adverse reactions listed above, across clinical trials of YERVOY monotherapy or in combination with OPDIVO, the following clinically significant immune-mediated adverse reactions, some with fatal outcome, occurred in <1% of patients unless otherwise specified: nervous system: autoimmune neuropathy (2%), myasthenic syndrome/myasthenia gravis, motor dysfunction; cardiovascular: angiopathy, temporal arteritis; ocular: blepharitis, episcleritis, orbital myositis, scleritis; gastrointestinal: pancreatitis (1.3%); other (hematologic/immune): conjunctivitis, cytopenias (2.5%), eosinophilia (2.1%), erythema multiforme, hypersensitivity vasculitis, neurosensory hypoacusis, psoriasis.

Some ocular IMAR cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, which has been observed in patients receiving YERVOY, as this may require treatment with systemic corticosteroids to reduce the risk of permanent vision loss.

**Please see Select Important Safety Information on page 14. Please see Brief Summary of Full Prescribing Information on pages 15 through 19.**

**Figure 4. Median duration of response (extended follow-up analysis in patients with PD-L1 ≥1%)**



Median follow-up of 43.1 months.

## IMPORTANT SAFETY INFORMATION

### Infusion-Related Reactions

OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue OPDIVO and YERVOY in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions.

### Complications of Allogeneic Hematopoietic Stem Cell Transplantation

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with OPDIVO or YERVOY. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between OPDIVO or YERVOY and allogeneic HSCT.

Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with OPDIVO and YERVOY prior to or after an allogeneic HSCT.

**Q:** Can you summarize the outcomes of this study and what data points you think are clinically meaningful?

**A:** The DOR for initial responders and the long-term OS of 1 in 3 patients (33% landmark OS for OPDIVO + YERVOY vs 22% for chemotherapy alone in patients with PD-L1  $\geq 1\%$ ) at the 3 year time mark are compelling pieces of evidence to me. Among OPDIVO + YERVOY responders at 6 months, 70% were alive at 3.5 years and 39% of patients who received chemotherapy alone (post-randomization) were alive at this time. Median DOR in the patients with PD-L1 expression  $\geq 1\%$  was 23.2 months in the OPDIVO + YERVOY arm and 6.7 months in the chemotherapy arm.

### **IMPORTANT SAFETY INFORMATION**

#### **Embryo-Fetal Toxicity**

Based on its mechanism of action and findings from animal studies, OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.

#### **Increased Mortality in Patients with Multiple Myeloma when OPDIVO is Added to a Thalidomide Analogue and Dexamethasone**

In randomized clinical trials in patients with multiple myeloma, the addition of OPDIVO to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

**Please see Select Important Safety Information on page 14. Please see Brief Summary of Full Prescribing Information on pages 15 through 19.**

**Q: How do you counsel your patients who receive OPDIVO + YERVOY as 1L therapy?**

**A:** I tell my patients, “If there are any changes in your body that you're noticing, I need to know about them and be informed immediately.” I ask patients to fill out a questionnaire every time they come for immunotherapy. We do this to establish a baseline to appreciate changes in their symptomatology. I tell my patients that they are my deputy sheriff when it comes to surveilling their own body and keeping me informed, and that together we can typically manage this very quickly.

In Checkmate 227, serious adverse reactions occurred in 58% of patients (N=576). The most frequent ( $\geq 2\%$ ) serious adverse reactions were pneumonia, diarrhea/colitis, pneumonitis, hepatitis, pulmonary embolism, adrenal insufficiency, and hypophysitis. Fatal adverse reactions occurred in 1.7% of patients; these included events of pneumonitis (4 patients), myocarditis, acute kidney injury, shock, hyperglycemia, multi-system organ failure, and renal failure.

In Checkmate 227, the most common ( $\geq 20\%$ ) adverse reactions were fatigue (44%), rash (34%), decreased appetite (31%), musculoskeletal pain (27%), diarrhea/colitis (26%), dyspnea (26%), cough (23%), hepatitis (21%), nausea (21%), and pruritus (21%).

OPDIVO and YERVOY were discontinued for adverse reactions in 24% of patients and 53% had at least one dose withheld for an adverse reaction.

**IMPORTANT SAFETY INFORMATION****Lactation**

There are no data on the presence of OPDIVO or YERVOY in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 5 months after the last dose.

**Serious Adverse Reactions**

In Checkmate 227, serious adverse reactions occurred in 58% of patients (n=576). The most frequent ( $\geq 2\%$ ) serious adverse reactions were pneumonia, diarrhea/colitis, pneumonitis, hepatitis, pulmonary embolism, adrenal insufficiency, and hypophysitis. Fatal adverse reactions occurred in 1.7% of patients; these included events of pneumonitis (4 patients), myocarditis, acute kidney injury, shock, hyperglycemia, multi-system organ failure, and renal failure.

**Common Adverse Reactions**

In Checkmate 227, the most common ( $\geq 20\%$ ) adverse reactions were fatigue (44%), rash (34%), decreased appetite (31%), musculoskeletal pain (27%), diarrhea/colitis (26%), dyspnea (26%), cough (23%), hepatitis (21%), nausea (21%), and pruritus (21%).

**Table 1. Adverse reactions in ≥10% of patients receiving OPDIVO (nivolumab) + YERVOY (ipilimumab)**

Adverse reactions	OPDIVO + YERVOY (n=576)		Chemo <sup>†††</sup> (n=570)	
	All grades (%)	Grades 3-4 (%)	All grades (%)	Grades 3-4 (%)
<b>General</b>				
Fatigue*	44	6	42	4.4
Pyrexia	18	0.5	11	0.4
Edema†	14	0.2	12	0.5
<b>Skin and subcutaneous tissue</b>				
Rash‡	34	4.7	10	0.4
Pruritus§	21	0.5	3.3	0
<b>Metabolism and nutrition</b>				
Decreased appetite	31	2.3	26	1.4
<b>Musculoskeletal and connective tissue</b>				
Musculoskeletal pain¶	27	1.9	16	0.7
Arthralgia	13	0.9	2.5	0.2
<b>Gastrointestinal</b>				
Diarrhea/colitis¶¶	26	3.6	16	0.9
Nausea	21	1.0	42	2.5
Constipation	18	0.3	27	0.5
Vomiting	13	1.0	18	2.3
Abdominal pain#	10	0.2	9	0.7
<b>Respiratory, thoracic, and mediastinal</b>				
Dyspnea**	26	4.3	16	2.1
Cough††	23	0.2	13	0
<b>Hepatobiliary</b>				
Hepatitis†††	21	9	10	1.2
<b>Endocrine</b>				
Hypothyroidism§§	16	0.5	1.2	0
Hyperthyroidism¶¶¶	10	0	0.5	0
<b>Infections and infestations</b>				
Pneumonia¶¶¶¶	13	7	8	4.0
<b>Nervous system</b>				
Headache	11	0.5	6	0

Safety was assessed in the overall population in Checkmate 227 Part 1. Efficacy analysis was conducted in the Part 1a population.<sup>4</sup>

\*Includes fatigue and asthenia.

†Includes eyelid edema, face edema, generalized edema, localized edema, edema, edema peripheral, and periorbital edema.

‡Includes autoimmune dermatitis, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, dermatitis contact, dermatitis exfoliative, dermatitis psoriasiform, granulomatous dermatitis, rash generalized, drug eruption, dyshidrotic eczema, eczema, exfoliative rash, nodular rash, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, toxic skin eruption.

§Includes pruritus and pruritus generalized.

¶Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, and pain in extremity.

¶¶Includes colitis, colitis microscopic, colitis ulcerative, diarrhea, enteritis infectious, enterocolitis, enterocolitis infectious, and enterocolitis viral.

#Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.

\*\*Includes dyspnea and dyspnea exertional.

††Includes cough and productive cough.

†††Includes alanine aminotransferase increased, aspartate aminotransferase increased, autoimmune hepatitis, blood bilirubin increased, hepatic enzyme increased, hepatic failure, hepatic function abnormal, hepatitis, hepatitis E, hepatocellular injury, hepatotoxicity, hyperbilirubinemia, immune-mediated hepatitis, liver function test abnormal, liver function test increased, transaminases increased.

§§Includes autoimmune thyroiditis, blood thyroid stimulating hormone increased, hypothyroidism, primary hypothyroidism, thyroiditis, and tri-iodothyronine free decreased.

¶¶¶Includes blood thyroid stimulating hormone decreased, hyperthyroidism, and tri-iodothyronine free increased.

¶¶¶¶Includes lower respiratory tract infection, lower respiratory tract infection bacterial, lung infection, pneumonia, pneumonia adenoviral, pneumonia aspiration, pneumonia bacterial, pneumonia klebsiella, pneumonia influenzal, pneumonia viral, atypical pneumonia, organizing pneumonia.

††††In Checkmate 227, patients in the comparator arm received up to 4 cycles of platinum-doublet chemo.

**Please see Select Important Safety Information on page 14. Please see Brief Summary of Full Prescribing Information on pages 15 through 19.**

Education of patients, clinical staff, and ancillary providers and the building of multidisciplinary teams to manage immunotherapy side effects are crucial to achieve the best individual outcomes. Seeing the response and being able to moderate the T cell-driven responses with the help of a steroid-based immunosuppressive regimen is a great opportunity.

I believe the most important part for monitoring the side effects is frequent visits in the beginning. We typically try to interface my visits halfway through their treatment cycle, assessments in the infusion areas, and then to encourage interactive communication typically by phone calls and patient portal to be able to recognize changes early on.

I truly encourage a proactive approach. I involve family members. I believe that is very important if they have help at home, home healthcare or other services. I try to involve them as well to bring to my attention any deficits.

This is a chemotherapy-free treatment approach. My impression is that a team comfortable with managing single-agent PD-1 immunotherapy will be able to manage combination therapy as the diagnostics, surveillance mechanisms, and treatment approaches are nearly identical.

**Q: Based on these data, what do you feel is the role for OPDIVO + YERVOY in the 1L treatment of patients with mNSCLC and PD-L1  $\geq$ 1%?**

**A:** I believe the combination of OPDIVO + YERVOY in the 1L setting for PD-L1–positive disease is a very viable combination that seems to have the potential across the different levels of positive PD-L1 expression. In Checkmate 227 Part 1a, PFS, ORR, and DOR were pre-specified descriptive analyses. The primary efficacy outcome measure was OS, and, the 3-year OS was 33% with OPDIVO + YERVOY and 22% with chemotherapy. The ORR was 36% (142/396, 95% CI, 31-41; CR=5.8%, PR=30.1%) with OPDIVO + YERVOY and 30% (119/397, 95% CI: 26-35; CR=1.8%, PR=28.2%) with chemotherapy. With a median follow-up of 43.1 months, the median DOR among OPDIVO + YERVOY responders was 23.2 months versus 6.7 months with chemotherapy. Thus, this dual I-O approach with OPDIVO + YERVOY is an option that offers the chance for durable, long-term survival for mNSCLC patients with PD-L1  $\geq$ 1%.

## SELECT IMPORTANT SAFETY INFORMATION

### Serious Adverse Reactions

In Checkmate 9LA, serious adverse reactions occurred in 57% of patients (n=358). The most frequent (>2%) serious adverse reactions were pneumonia, diarrhea, febrile neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis, and respiratory failure. Fatal adverse reactions occurred in 7 (2%) patients, and included hepatic toxicity, acute renal failure, sepsis, pneumonitis, diarrhea with hypokalemia, and massive hemoptysis in the setting of thrombocytopenia.

### Common Adverse Reactions

In Checkmate 9LA, the most common (>20%) adverse reactions were fatigue (49%), musculoskeletal pain (39%), nausea (32%), diarrhea (31%), rash (30%), decreased appetite (28%), constipation (21%), and pruritus (21%).

### Checkmate Trials and Patient Populations

Checkmate 9LA—previously untreated recurrent or metastatic non-small cell lung cancer in combination with YERVOY and 2 cycles of platinum-doublet chemotherapy by histology.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;67(1):7-30.
2. American Cancer Society. Key Statistics for Lung Cancer. 2020. [www.cancer.org/cancer/lung-cancer/about/key-statistics.html](http://www.cancer.org/cancer/lung-cancer/about/key-statistics.html). Accessed on July 1, 2020.
3. OpdivoYervoymNSCLC. [www.opdivoyervoymnsclc.com](http://www.opdivoyervoymnsclc.com). Accessed on July 1, 2020.
4. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
5. YERVOY [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
6. Weber JS, Hamid O, Chesalov SD, et al. Ipilimumab increased activated T cells and enhances humoral immunity in patients with advanced melanoma. *J Immunother*. 2012;35:89-97.
7. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, and anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. *Clin Cancer Res*. 2009;15:6446-6463.
8. Farber DL, Yudanin NA, Restifo NP, et al. Human memory T cells: generation, compartmentalization, and homeostasis. *Nat Rev Immunol*. 2014;14:24-35.
9. Felix J, Lambert J, Roelens M, et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. *Oncoimmunology*. 2016;5:e1136045-1-e1136045-10.
10. Pedicord VA, Montalvo W, Leiner IM, et al. Single dose of anti-CTLA-4 enhances CD8+ t-memory formation, function, and maintenance. *Proc Natl Acad Sci USA*. 2011;108:266-271.
11. Pico de Coana Y, Wolodarski M, Poschke I, et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. *Oncotarget*. 2017;8:21539-21553.
12. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncol*. 2017;18:31-41.
13. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. *N Engl J Med*. 2019;381:2020-2031.
14. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer [supplementary appendix]. *N Engl J Med*. 2019;381:2020-2031.
15. Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. Oral presentation at ASCO 2020. Abstract 9500.

**Please see Brief Summary of Full Prescribing Information for OPDIVO and YERVOY on pages 15 through 19.**

# OPDIVO® (nivolumab) injection, for intravenous use Rx ONLY

Brief Summary of Prescribing Information. For complete prescribing information consult official package insert.

## INDICATIONS AND USAGE

- OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test [see *Dosage and Administration*], with no EGFR or ALK genomic tumor aberrations.
- OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

## DOSAGE AND ADMINISTRATION

### Patient Selection

Select patients with metastatic NSCLC for treatment with OPDIVO in combination with ipilimumab based on PD-L1 expression [see *Clinical Studies (14.3) in full Prescribing Information*]. Information on FDA-approved tests for the determination of PD-L1 expression in NSCLC is available at: <http://www.fda.gov/CompanionDiagnostics>.

### CONTRAINDICATIONS

None.

## WARNINGS AND PRECAUTIONS

### Severe and Fatal Immune-Mediated Adverse Reactions

OPDIVO is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatal immune-mediated reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD 1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue OPDIVO depending on severity [see *Dosage and Administration (2.1) in full Prescribing Information*]. In general, if OPDIVO requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

### Immune-Mediated Pneumonitis

OPDIVO can cause immune-mediated pneumonitis, which is defined as requiring use of steroids and no clear alternate etiology. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation.

In NSCLC, immune-mediated pneumonitis occurred in 9% (50/576) of patients receiving OPDIVO 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%) immune-mediated pneumonitis. Four patients (0.7%) died due to pneumonitis. Immune-mediated pneumonitis led to permanent discontinuation of OPDIVO with ipilimumab in 5% of patients and withholding of OPDIVO with ipilimumab in 3.6% of patients.

Systemic corticosteroids were required in 100% of patients with pneumonitis. Pneumonitis resolved in 72% of the patients. Approximately 13% (2/16) of patients had recurrence of pneumonitis after reinitiation of OPDIVO with ipilimumab.

### Immune-Mediated Colitis

OPDIVO can cause immune-mediated colitis, defined as requiring use of corticosteroids and no clear alternate etiology. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

### Immune-Mediated Hepatitis

OPDIVO can cause immune-mediated hepatitis, defined as requiring the use of corticosteroids and no clear alternate etiology.

### Immune-Mediated Endocrinopathies

#### Adrenal Insufficiency

OPDIVO can cause primary or secondary adrenal insufficiency. For grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold OPDIVO depending on severity [see *Dosage and Administration (2.2) in full Prescribing Information*].

#### Hypophysitis

OPDIVO can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue OPDIVO depending on severity [see *Dosage and Administration (2.2) in full Prescribing Information*].

#### Thyroid Disorders

OPDIVO can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement or medical management as clinically indicated. Withhold or permanently discontinue OPDIVO depending on severity [see *Dosage and Administration (2.2) in full Prescribing Information*].

#### Type 1 Diabetes Mellitus, which can present with Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold OPDIVO depending on severity [see *Dosage and Administration (2.2) in full Prescribing Information*].

### Immune-Mediated Nephritis and Renal Dysfunction

OPDIVO can cause immune-mediated nephritis, which is defined as requiring use of steroids and no clear alternate etiology.

### Immune-Mediated Dermatologic Adverse Reactions

OPDIVO can cause immune-mediated rash or dermatitis, defined as requiring the use of steroids and no clear alternate etiology. Exfoliative dermatitis, including Stevens-Johnson Syndrome, toxic epidermal necrolysis (TEN), and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) has occurred with PD-1/L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue OPDIVO depending on severity [see *Dosage and Administration (2.2) in full Prescribing Information*].

### Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received OPDIVO or OPDIVO in combination with ipilimumab, or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.

#### Cardiac/Vascular: Myocarditis, pericarditis, vasculitis

**Nervous System:** Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barre syndrome, nerve palsy, autoimmune neuropathy

**Ocular:** Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss

**Gastrointestinal:** Pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis

**Musculoskeletal and Connective Tissue:** Myositis/polymyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatic

**Endocrine:** Hypoparathyroidism

**Other (Hematologic/Immune):** Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection

## Infusion-Related Reactions

OPDIVO (nivolumab) can cause severe infusion-related reactions, which have been reported in <1.0% of patients in clinical trials. Discontinue OPDIVO in patients with severe or life-threatening infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion-related reactions [see *Dosage and Administration (2.3) in full Prescribing Information*].

## Complications of Allogeneic Hematopoietic Stem Cell Transplantation

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1 receptor blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause) [see *Adverse Reactions*]. These complications may occur despite intervening therapy between PD-1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1 receptor blocking antibody prior to or after an allogeneic HSCT.

## Embryo-Fetal Toxicity

Based on its mechanism of action and data from animal studies, OPDIVO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of nivolumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in increased abortion and premature infant death. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and for at least 5 months after the last dose [see *Use in Specific Populations*].

## Increased Mortality in Patients with Multiple Myeloma when OPDIVO is Added to a Thalidomide Analogue and Dexamethasone

In randomized clinical trials in patients with multiple myeloma, the addition of a PD-1 blocking antibody, including OPDIVO, to a thalidomide analogue plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

## ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling [see *Warnings and Precautions*]: Severe and Fatal Immune-Mediated Adverse Reactions, Infusion-Related Reactions, Complications of Allogeneic HSCT.

### Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in WARNINGS AND PRECAUTIONS reflect exposure to OPDIVO as a single agent in 1994 patients enrolled in CHECKMATE-037, CHECKMATE-017, CHECKMATE-057, CHECKMATE-066, CHECKMATE-067, CHECKMATE-025, CHECKMATE-067, CHECKMATE-205, CHECKMATE-039 or a single-arm trial in NSCLC (n=117); OPDIVO 1 mg/kg with ipilimumab 3 mg/kg in patients enrolled in CHECKMATE-067 (n=313), CHECKMATE-040 (n=49), or another randomized trial (n=94); OPDIVO 3 mg/kg administered with ipilimumab 1 mg/kg (n=666) in patients enrolled in CHECKMATE-214 or CHECKMATE-142; OPDIVO 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks in patients enrolled in CHECKMATE-227 (n=576) or CHECKMATE-743 (n=300); and OPDIVO 360 mg with ipilimumab 1 mg/kg and 2 cycles of platinum-doublet chemotherapy in CHECKMATE-9LA (n=361).

### Metastatic Non-Small Cell Lung Cancer

#### First-Line Treatment of Metastatic NSCLC: In Combination with Ipilimumab

The safety of OPDIVO in combination with ipilimumab was evaluated in CHECKMATE-227, a randomized, multicenter, multi-cohort, open-label trial in patients with previously untreated metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations [see *Clinical Studies (14.3) in full Prescribing Information*]. The trial excluded patients with untreated brain metastases, carcinomatous meningitis, active autoimmune disease, or medical conditions requiring systemic immunosuppression. Patients received OPDIVO 3 mg/kg by intravenous infusion over 30 minutes every 2 weeks and ipilimumab 1 mg/kg by intravenous infusion over 30 minutes every 6 weeks or platinum-doublet chemotherapy every 3 weeks for 4 cycles. The median duration of therapy in OPDIVO and ipilimumab-treated patients was 4.2 months (range: 1 day to 25.5 months); 39% of patients received OPDIVO and ipilimumab for >6 months and 23% of patients received OPDIVO and ipilimumab for >1 year. The population characteristics were: median age 64 years (range: 26 to 87); 48% were ≥65 years of age, 76% White, and 67% male. Baseline ECOG performance status was 0 (35%) or 1 (65%), 85% were former/current smokers, 11% had brain metastases, 28% had squamous histology and 72% had non-squamous histology.

Serious adverse reactions occurred in 58% of patients. OPDIVO and ipilimumab were discontinued for adverse reactions in 24% of patients and 53% had at least one dose withheld for an adverse reaction. The most frequent (≥2%) serious adverse reactions were pneumonia, diarrhea/colitis, pneumonitis, hepatitis, pulmonary embolism, adrenal insufficiency, and hypophysitis. Fatal adverse reactions occurred in 1.7% of patients; these included events of pneumonitis (4 patients), myocarditis, acute kidney injury, shock, hyperglycemia, multi-system organ failure, and renal failure. The most common (≥20%) adverse reactions were fatigue, rash, decreased appetite, musculoskeletal pain, diarrhea/colitis, dyspnea, cough, hepatitis, nausea, and pruritus. Tables 1 and 2 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-227.

**Table 1: Adverse Reactions in ≥10% of Patients Receiving OPDIVO and Ipilimumab - CHECKMATE-227**

Adverse Reaction	OPDIVO and Ipilimumab (n=576)		Platinum-doublet Chemotherapy (n=570)	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
<b>General</b>				
Fatigue <sup>a</sup>	44	6	42	4.4
Pyrexia	18	0.5	11	0.4
Edema <sup>b</sup>	14	0.2	12	0.5
<b>Skin and Subcutaneous Tissue</b>				
Rash <sup>c</sup>	34	4.7	10	0.4
Pruritus <sup>d</sup>	21	0.5	3.3	0
<b>Metabolism and Nutrition</b>				
Decreased appetite	31	2.3	26	1.4
<b>Musculoskeletal and Connective Tissue</b>				
Musculoskeletal pain <sup>e</sup>	27	1.9	16	0.7
Arthralgia	13	0.9	2.5	0.2
<b>Gastrointestinal</b>				
Diarrhea/colitis <sup>f</sup>	26	3.6	16	0.9
Nausea	21	1.0	42	2.5
Constipation	18	0.3	27	0.5
Vomiting	13	1.0	18	2.3
Abdominal pain <sup>g</sup>	10	0.2	9	0.7
<b>Respiratory, Thoracic, and Mediastinal</b>				
Dyspnea <sup>h</sup>	26	4.3	16	2.1
Cough <sup>i</sup>	23	0.2	13	0
<b>Hepatobiliary</b>				
Hepatitis <sup>j</sup>	21	9	10	1.2
<b>Endocrine</b>				
Hypothyroidism <sup>k</sup>	16	0.5	1.2	0
Hyperthyroidism <sup>l</sup>	10	0	0.5	0
<b>Infections and Infestations</b>				
Pneumonia <sup>m</sup>	13	7	8	4.0

(Continued)

**Table 1: Adverse Reactions in ≥10% of Patients Receiving OPDIVO (nivolumab) and Ipilimumab - CHECKMATE-227 (Continued)**

Adverse Reaction	OPDIVO and Ipilimumab (n=576)		Platinum-doublet Chemotherapy (n=570)	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
<b>Nervous System</b>				
Headache	11	0.5	6	0

- a Includes fatigue and asthenia.  
b Includes eyelid edema, face edema, generalized edema, localized edema, edema, edema peripheral, and periorbital edema.  
c Includes autoimmune dermatitis, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, dermatitis contact, dermatitis exfoliative, dermatitis psoriasiform, granulomatous dermatitis, rash generalized, drug eruption, dyshidrotic eczema, eczema, exfoliative rash, nodular rash, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, toxic skin eruption.  
d Includes pruritus and pruritus generalized.  
e Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, and pain in extremity.  
f Includes colitis, colitis microscopic, colitis ulcerative, diarrhea, enteritis infectious, enterocolitis, enterocolitis infectious, and enterocolitis viral.  
g Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.  
h Includes dyspnea and dyspnea exertional.  
i Includes cough and productive cough.  
j Includes alanine aminotransferase increased, aspartate aminotransferase increased, autoimmune hepatitis, blood bilirubin increased, hepatic enzyme increased, hepatic failure, hepatic function abnormal, hepatitis B, hepatitis E, hepatocellular injury, hepatotoxicity, hyperbilirubinemia, immune-mediated hepatitis, liver function test abnormal, liver function test increased, transaminases increased.  
k Includes autoimmune thyroiditis, blood thyroid stimulating hormone increased, hypothyroidism, primary hypothyroidism, thyroiditis, and tri-iodothyronine free decreased.  
l Contains blood thyroid stimulating hormone decreased, hyperthyroidism, and tri-iodothyronine free increased.  
m Includes lower respiratory tract infection, lower respiratory tract infection bacterial, lung infection, pneumonia, pneumonia adenoviral, pneumonia aspiration, pneumonia bacterial, pneumonia klebsiella, pneumonia influenza, pneumonia viral, atypical pneumonia, organizing pneumonia.

Other clinically important adverse reactions in CHECKMATE-227 were: *Skin and Subcutaneous Tissue*: urticaria, alopecia, erythema multiforme, vitiligo; *Gastrointestinal*: stomatitis, pancreatitis, gastritis; *Musculoskeletal and Connective Tissue*: arthritis, polymyalgia rheumatica, rhabdomyolysis; *Nervous System*: peripheral neuropathy, autoimmune encephalitis; *Blood and Lymphatic System*: eosinophilia; *Eye Disorders*: blurred vision, uveitis; *Cardiac*: atrial fibrillation, myocarditis.

**Table 2: Laboratory Values Worsening from Baseline<sup>a</sup> Occurring in ≥20% of Patients on OPDIVO and Ipilimumab - CHECKMATE-227**

Laboratory Abnormality	OPDIVO and Ipilimumab		Platinum-doublet Chemotherapy	
	Grades 1-4 (%)	Grades 3-4 (%)	Grades 1-4 (%)	Grades 3-4 (%)
<b>Hematology</b>				
Anemia	46	3.6	78	14
Lymphopenia	46	5	60	15
<b>Chemistry</b>				
Hyponatremia	41	12	26	4.9
Increased AST	39	5	26	0.4
Increased ALT	36	7	27	0.7
Increased lipase	35	14	14	3.4
Increased alkaline phosphatase	34	3.8	20	0.2
Increased amylase	28	9	18	1.9
Hypocalcemia	28	1.7	17	1.3
Hyperkalemia	27	3.4	22	0.4
Increased creatinine	22	0.9	17	0.2

<sup>a</sup> Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: OPDIVO and ipilimumab group (range: 494 to 556 patients) and chemotherapy group (range: 469 to 542 patients).

**First-line Treatment of Metastatic or Recurrent NSCLC: In Combination with Ipilimumab and Platinum-Doublet Chemotherapy**

The safety of OPDIVO in combination with ipilimumab and platinum-doublet chemotherapy was evaluated in CHECKMATE-9LA [see Clinical Studies (14.3) in full Prescribing Information]. Patients received either OPDIVO 360 mg administered every 3 weeks in combination with ipilimumab 1 mg/kg administered every 6 weeks and platinum-doublet chemotherapy administered every 3 weeks for 2 cycles; or platinum-doublet chemotherapy administered every 3 weeks for 4 cycles. The median duration of therapy in OPDIVO in combination with ipilimumab and platinum-doublet chemotherapy was 6 months (range: 1 day to 19 months); 50% of patients received OPDIVO and ipilimumab for >6 months and 13% of patients received OPDIVO and ipilimumab for >1 year.

Serious adverse reactions occurred in 57% of patients who were treated with OPDIVO in combination with ipilimumab and platinum-doublet chemotherapy. The most frequent (>2%) serious adverse reactions were pneumonia, diarrhea, febrile neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis, and respiratory failure. Fatal adverse reactions occurred in 7 (2%) patients, and included hepatic toxicity, acute renal failure, sepsis, pneumonitis, diarrhea with hypokalemia, and massive hemoptysis in the setting of thrombocytopenia.

Study therapy with OPDIVO in combination with ipilimumab and platinum-doublet chemotherapy was permanently discontinued for adverse reactions in 24% of patients and 56% had at least one treatment withheld for an adverse reaction. The most common (>20%) adverse reactions were fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus.

Tables 3 and 4 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-9LA.

**Table 3: Adverse Reactions in >10% of Patients Receiving OPDIVO and Ipilimumab and Platinum-Doublet Chemotherapy - CHECKMATE-9LA**

Adverse Reaction	OPDIVO and Ipilimumab and Platinum-Doublet Chemotherapy (n=358)		Platinum-Doublet Chemotherapy (n=349)	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
<b>General</b>				
Fatigue <sup>a</sup>	49	5	40	4.9
Pyrexia	14	0.6	10	0.6
<b>Musculoskeletal and Connective Tissue</b>				
Musculoskeletal pain <sup>b</sup>	39	4.5	27	2.0
<b>Gastrointestinal</b>				
Nausea	32	1.7	41	0.9
Diarrhea <sup>c</sup>	31	6	18	1.7
Constipation	21	0.6	23	0.6
Vomiting	18	2.0	17	1.4
Abdominal pain <sup>d</sup>	12	0.6	11	0.9
<b>Skin and Subcutaneous Tissue</b>				
Rash <sup>e</sup>	30	4.7	10	0.3
Pruritus <sup>f</sup>	21	0.8	2.9	0
Alopecia	11	0.8	10	0.6
<b>Metabolism and Nutrition</b>				
Decreased appetite	28	2.0	22	1.7

(Continued)

**Table 3: Adverse Reactions in >10% of Patients Receiving OPDIVO (nivolumab) and Ipilimumab and Platinum-Doublet Chemotherapy - CHECKMATE-9LA (Continued)**

Adverse Reaction	OPDIVO and Ipilimumab and Platinum-Doublet Chemotherapy (n=358)		Platinum-Doublet Chemotherapy (n=349)	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
<b>Respiratory, Thoracic and Mediastinal</b>				
Cough <sup>g</sup>	19	0.6	15	0.9
Dyspnea <sup>h</sup>	18	4.7	14	3.2
<b>Endocrine</b>				
Hypothyroidism <sup>i</sup>	19	0.3	3.4	0
<b>Nervous System</b>				
Headache	11	0.6	7	0
Dizziness <sup>j</sup>	11	0.6	6	0

Toxicity was graded per NCI CTCAE v4.

- a Includes fatigue and asthenia  
b Includes myalgia, back pain, pain in extremity, musculoskeletal pain, bone pain, flank pain, muscle spasms, musculoskeletal chest pain, musculoskeletal disorder, osteitis, musculoskeletal stiffness, non-cardiac chest pain, arthralgia, arthritis, arthropathy, joint effusion, psoriatic arthropathy, synovitis  
c Includes colitis, ulcerative colitis, diarrhea, and enterocolitis  
d Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and gastrointestinal pain  
e Includes acne, dermatitis, acneiform dermatitis, allergic dermatitis, atopic dermatitis, bullous dermatitis, generalized exfoliative dermatitis, eczema, keratoderma blenorrhagica, palmar-plantar erythrodysesthesia syndrome, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, morbilliform rash, papular rash, pruritic rash, skin exfoliation, skin reaction, skin toxicity, Stevens-Johnson syndrome, urticaria  
f Includes pruritus and generalized pruritus  
g Includes cough, productive cough, and upper-airway cough syndrome  
h Includes dyspnea, dyspnea at rest, and exertional dyspnea  
i Includes autoimmune thyroiditis, increased blood thyroid stimulating hormone, hypothyroidism, thyroiditis, and decreased free tri-iodothyronine  
j Includes dizziness, vertigo and positional vertigo

**Table 4: Laboratory Values Worsening from Baseline<sup>a</sup> Occurring in >20% of Patients on OPDIVO and Ipilimumab and Platinum-Doublet Chemotherapy - CHECKMATE-9LA**

Laboratory Abnormality	OPDIVO and Ipilimumab and Platinum-Doublet Chemotherapy		Platinum-Doublet Chemotherapy	
	Grades 1-4 (%)	Grades 3-4 (%)	Grades 1-4 (%)	Grades 3-4 (%)
<b>Hematology</b>				
Anemia	70	9	74	16
Lymphopenia	41	6	40	11
Neutropenia	40	15	42	15
Leukopenia	36	10	40	9
Thrombocytopenia	23	4.3	24	5
<b>Chemistry</b>				
Hyperglycemia	45	7	42	2.6
Hyponatremia	37	10	27	7
Increased ALT	34	4.3	24	1.2
Increased lipase	31	12	10	2.2
Increased alkaline phosphatase	31	1.2	26	0.3
Increased amylase	30	7	19	1.3
Increased AST	29	3.5	22	0.3
Hypomagnesemia	29	1.2	33	0.6
Hypocalcemia	26	1.4	22	1.8
Increased creatinine	26	1.2	23	0.6
Hyperkalemia	22	1.7	21	2.1

<sup>a</sup> Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: OPDIVO and ipilimumab and platinum-doublet chemotherapy group (range: 197 to 347 patients) and platinum-doublet chemotherapy group (range: 191 to 335 patients).

**Immunogenicity**

As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to OPDIVO with the incidences of antibodies to other products may be misleading.

Of the patients with metastatic or recurrent NSCLC who were treated with OPDIVO and ipilimumab and evaluable for the presence of anti-nivolumab antibodies, the incidence of anti-nivolumab antibodies was 36.7% (180/491) with OPDIVO 3 mg/kg every 2 weeks and ipilimumab 1 mg every 6 weeks. The incidence of neutralizing antibodies against nivolumab was 1.4% (7/491) with OPDIVO 3 mg/kg every 2 weeks and ipilimumab 1 mg every 6 weeks.

Of the patients with NSCLC who were treated with OPDIVO 360 mg every 3 weeks in combination with ipilimumab 1 mg/kg every 6 weeks and platinum-doublet chemotherapy, and were evaluable for the presence of anti-nivolumab antibodies, the incidence of anti-nivolumab antibodies was 34% (104/308); the incidence of neutralizing antibodies against nivolumab was 2.6% (8/308).

There was no evidence of increased incidence of infusion-related reactions with anti-nivolumab antibody development.

**Postmarketing Experience**

The following adverse reactions have been identified during postapproval use of OPDIVO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. *Eye*: Vogt-Koyanagi-Harada (VKH) syndrome; *Complications of OPDIVO Treatment After Allogeneic HSCT*: treatment refractory, severe acute and chronic GVHD; *Blood and lymphatic system disorders*: hemophagocytic lymphohistiocytosis (HLH) (including fatal cases), autoimmune hemolytic anemia (including fatal cases).

**USE IN SPECIFIC POPULATIONS**

**PREGNANCY**

**Risk Summary**

Based on data from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) in full Prescribing Information], OPDIVO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of nivolumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in increased abortion and premature infant death (see Data). Human IgG4 is known to cross the placental barrier and nivolumab is an immunoglobulin G4 (IgG4); therefore, nivolumab has the potential to be transmitted from the mother to the developing fetus. The effects of OPDIVO are likely to be greater during the second and third trimesters of pregnancy. There are no available data on OPDIVO use in pregnant women to evaluate a drug-associated risk. Advise pregnant women of the potential risk to a fetus.

The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.

**Data**

**Animal Data**

A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. Blockade of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the fetus and to increase fetal loss. The effects of nivolumab on prenatal and postnatal development were evaluated in monkeys that received nivolumab twice weekly from the onset of organogenesis through delivery, at exposure levels of between 9 and 42 times higher than those observed at the clinical dose of 3 mg/kg (based on AUC). Nivolumab administration

resulted in a non-dose-related increase in spontaneous abortion and increased neonatal death. Based on its mechanism of action, fetal exposure to nivolumab may increase the risk of developing immune-mediated disorders or altering the normal immune response and immune-mediated disorders have been reported in PD-1 knockout mice. In surviving infants (18 of 32 compared to 11 of 16 vehicle-exposed infants) of cynomolgus monkeys treated with nivolumab, there were no apparent malformations and no effects on neurobehavioral, immunological, or clinical pathology parameters throughout the 6-month postnatal period.

#### Lactation

##### Risk Summary

There are no data on the presence of nivolumab in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment and for 5 months after the last dose of OPDIVO (nivolumab).

#### Females and Males of Reproductive Potential

##### Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating OPDIVO [see Use in Specific Populations–Pregnancy].

##### Contraception

OPDIVO can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations–Pregnancy]. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and for at least 5 months following the last dose.

##### Pediatric Use

The safety and effectiveness of OPDIVO and YERVOY (ipilimumab) have not been established in pediatric patients less than 18 years old with NSCLC [see Indications and Usage].

##### Geriatric Use

Of the 576 patients randomized to OPDIVO 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks in CHECKMATE-227 (NSCLC), 48% were 65 years or older and 10% were 75 years or older. No overall difference in safety was reported between older patients and younger patients; however, there was a higher discontinuation rate due to adverse reactions in patients aged 75 years or older (29%) relative to all patients who received OPDIVO with ipilimumab (18%). Of the 396 patients in the primary efficacy population (PD-L1  $\geq 1\%$ ) randomized to OPDIVO 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks in CHECKMATE-227, the hazard ratio for overall survival was 0.70 (95% CI: 0.55, 0.89) in the 199 patients younger than 65 years compared to 0.91 (95% CI: 0.72, 1.15) in the 197 patients 65 years or older [see Clinical Studies (14.3) in full Prescribing Information].

Of the 361 patients randomized to OPDIVO 360 mg every 3 weeks in combination with ipilimumab 1 mg/kg every 6 weeks and platinum-doublet chemotherapy every 3 weeks (for 2 cycles) in CHECKMATE-9LA (NSCLC), 51% were 65 years or older and 10% were 75 years or older. No overall difference in safety was reported between older patients and younger patients; however, there was a higher discontinuation rate due to adverse reactions in patients aged 75 years or older (43%) relative to all patients who received OPDIVO with ipilimumab and chemotherapy (24%). For patients aged 75 years or older who received chemotherapy only, the discontinuation rate due to adverse reactions was 16% relative to all patients who had a discontinuation rate of 13%. Based on an updated analysis for overall survival, of the 361 patients randomized to OPDIVO in combination with ipilimumab and platinum-doublet chemotherapy in CHECKMATE-9LA, the hazard ratio for overall survival was 0.61 (95% CI: 0.47, 0.80) in the 176 patients younger than 65 years compared to 0.73 (95% CI: 0.56, 0.95) in the 185 patients 65 years or older.

#### PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

##### Immune-Mediated Adverse Reactions

Inform patients of the risk of immune-mediated adverse reactions that may require corticosteroid treatment and withholding or discontinuation of OPDIVO (nivolumab), including:

- Pneumonitis: Advise patients to contact their healthcare provider immediately for any new or worsening cough, chest pain, or shortness of breath [see Warnings and Precautions]
- Colitis: Advise patients to contact their healthcare provider immediately for diarrhea or severe abdominal pain [see Warnings and Precautions]
- Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, pain on the right side of abdomen, lethargy, or easy bruising or bleeding [see Warnings and Precautions]
- Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypophysitis, adrenal insufficiency, hypothyroidism, hyperthyroidism, and diabetes mellitus [see Warnings and Precautions]
- Nephritis and Renal Dysfunction: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis including decreased urine output, blood in urine, swelling in ankles, loss of appetite, and any other symptoms of renal dysfunction [see Warnings and Precautions]
- Skin Adverse Reactions: Advise patients to contact their healthcare provider immediately for rash [see Warnings and Precautions].

##### Infusion-Related Reactions

- Advise patients of the potential risk of infusion-related reactions [see Warnings and Precautions].

##### Complications of Allogeneic HSCT

- Advise patients of potential risk of post-transplant complications [see Warnings and Precautions].

##### Embryo-Fetal Toxicity

- Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions, Use in Specific Populations].
- Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and for at least 5 months following the last dose [see Use in Specific Populations].

##### Lactation

- Advise women not to breastfeed during treatment with OPDIVO and for 5 months after the last dose [see Use in Specific Populations].

Manufactured by:  
Bristol-Myers Squibb Company  
Princeton, NJ 08543 USA  
U.S. License No. 1713

Revised: November 2020

# YERVOY® (ipilimumab) injection, for intravenous use Rx ONLY

Brief Summary of Prescribing Information. For complete prescribing information consult official package insert.

#### INDICATIONS AND USAGE

- YERVOY (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 ( $\geq 1\%$ ) as determined by an FDA-approved test, [see Dosage and Administration], with no EGFR or ALK genomic tumor aberrations.
- YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.

#### DOSE AND ADMINISTRATION

##### Patient Selection

Select patients with metastatic NSCLC for treatment with YERVOY in combination with nivolumab based on PD-L1 expression [see Clinical Studies (14.6) in full Prescribing Information]. Information on FDA-approved tests for the determination of PD-L1 expression in NSCLC is available at: <http://www.fda.gov/CompanionDiagnostics>.

##### CONTRAINDICATIONS

None.

#### WARNINGS AND PRECAUTIONS

##### Severe and Fatal Immune-Mediated Adverse Reactions

YERVOY is a fully human monoclonal antibody that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, thereby removing inhibition of the immune response with the potential for induction of immune-mediated adverse reactions. Immune-mediated adverse reactions listed herein may not be inclusive of all possible severe and fatal immune-mediated reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting YERVOY. While immune-mediated adverse reactions usually manifest during treatment, immune-mediated adverse reactions can also manifest after discontinuation of YERVOY. Early identification and management are essential to ensure safe use of YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue YERVOY depending on severity [see Dosage and Administration (2.3) in full Prescribing Information]. In general, if YERVOY requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

##### Immune-Mediated Colitis

YERVOY can cause immune-mediated colitis, which may be fatal. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

##### Immune-Mediated Dermatologic Adverse Reactions

YERVOY can cause immune-mediated rash or dermatitis, including bullous and exfoliative dermatitis, Stevens Johnson Syndrome, toxic epidermal necrolysis (TEN), and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms). Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes. Withhold or permanently discontinue YERVOY depending on severity [see Dosage and Administration (2.3) in full Prescribing Information].

##### Immune-Mediated Endocrinopathies

###### Hypophysitis:

YERVOY can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue YERVOY depending on severity [see Dosage and Administration (2.3) in full Prescribing Information].

##### Immune-Mediated Pneumonitis

In NSCLC, immune-mediated pneumonitis occurred in 9% (50/576) of patients receiving YERVOY (ipilimumab) 1 mg/kg every 6 weeks with nivolumab 3 mg/kg every 2 weeks, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%) immune-mediated pneumonitis. Four patients (0.7%) died due to pneumonitis. The median duration was 1.5 months (range: 5 days to 25+ months). Immune-mediated pneumonitis led to permanent discontinuation of YERVOY with nivolumab in 5% of patients and withholding of YERVOY with nivolumab in 3.6% of patients.

Systemic corticosteroids were required in 100% of patients with pneumonitis followed by a corticosteroid taper. Pneumonitis resolved in 72% of the patients. Approximately 13% (2/16) of patients had recurrence of pneumonitis after re-initiation of YERVOY with nivolumab.

##### Other Immune-Mediated Adverse Reactions

Across clinical trials of YERVOY administered as a single agent or in combination with nivolumab, the following clinically significant immune-mediated adverse reactions, some with fatal outcome, occurred in <1% of patients unless otherwise specified, as shown below:

**Nervous System:** Autoimmune neuropathy (2%), meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, nerve paresthesia, motor dysfunction

**Cardiovascular:** Angiopathy, myocarditis, pericarditis, temporal arteritis, vasculitis

**Ocular:** Blepharitis, episcleritis, iritis, orbital myositis, scleritis, uveitis. Some cases can be associated with retinal detachment. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, which has been observed in patients receiving YERVOY and may require treatment with systemic corticosteroids to reduce the risk of permanent vision loss.

**Gastrointestinal:** Duodenitis, gastritis, pancreatitis (1.3%)

**Musculoskeletal and Connective Tissue:** Arthritis, myositis, polymyalgia rheumatica, polymyositis, rhabdomyolysis

**Other (hematologic/immune):** Aplastic anemia, conjunctivitis, cytopenias (2.5%), eosinophilia (2.1%), erythema multiforme, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), hypersensitivity vasculitis, meningitis, neurosensory hypoacusis, psoriasis, sarcoidosis, systemic inflammatory response syndrome

##### Infusion-Related Reactions

Severe infusion-related reactions can occur with YERVOY. Discontinue YERVOY in patients with severe or life-threatening infusion reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion reactions [see Dosage and Administration (2.3) in full Prescribing Information].

##### Complications of Allogeneic Hematopoietic Stem Cell Transplant after YERVOY

Fatal or serious graft-versus-host disease (GVHD) can occur in patients who receive YERVOY either before or after allogeneic hematopoietic stem cell transplantation (HSCT). These complications may occur despite intervening therapy between CTLA-4 receptor blocking antibody and allogeneic HSCT.

Follow patients closely for evidence of GVHD and intervene promptly [see Adverse Reactions]. Consider the benefit versus risks of treatment with YERVOY after allogeneic HSCT.

##### Embryo-Fetal Toxicity

Based on its mechanism of action and findings from animal studies, YERVOY can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of ipilimumab to cynomolgus monkeys from the onset of oogenesis through delivery resulted in higher incidences of abortion, stillbirth, premature delivery (with corresponding lower birth weight), and higher incidences of infant mortality in a dose-related manner. The effects of ipilimumab are likely to be greater during the second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with YERVOY and for 3 months after the last dose [see Use in Specific Populations].

##### Risks Associated When Administered in Combination with Nivolumab

When YERVOY is administered in combination with nivolumab, refer to the nivolumab Full Prescribing Information for additional risk information that applies to the combination use treatment.

#### ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Severe and fatal immune-mediated adverse reactions [see Warnings and Precautions].
- Infusion-related reactions [see Warnings and Precautions].

### Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The data described in the Warnings and Precautions section reflect exposure to YERVOY (ipilimumab) 1 mg/kg administered with nivolumab 3 mg/kg in CHECKMATE-227 and to YERVOY 1 mg/kg, administered in combination with nivolumab and platinum-doublet chemotherapy in CHECKMATE-9LA, an open-label, multicenter, randomized trial in adult patients with previously untreated metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

#### First-line Treatment of Metastatic NSCLC: In Combination with Nivolumab

The safety of YERVOY in combination with nivolumab was evaluated in CHECKMATE-227, a randomized, multicenter, multi-cohort, open-label trial in patients with previously untreated metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations [see *Clinical Studies (14.6) in full Prescribing Information*]. The trial excluded patients with untreated brain metastases, carcinomatous meningitis, active autoimmune disease, or medical conditions requiring systemic immunosuppression. Patients received YERVOY 1 mg/kg by intravenous infusion over 30 minutes every 6 weeks and nivolumab 3 mg/kg by intravenous infusion over 30 minutes every 2 weeks or platinum-doublet chemotherapy every 3 weeks for 4 cycles. The median duration of therapy in YERVOY and nivolumab-treated patients was 4.2 months (range: 1 day to 25.5 months); 39% of patients received YERVOY and nivolumab for >6 months and 23% of patients received YERVOY and nivolumab for >1 year. The population characteristics were: median age 64 years (range: 26 to 87); 48% were ≥65 years of age, 76% White, and 67% male. Baseline ECOG performance status was 0 (35%) or 1 (65%), 85% were former/current smokers, 11% had brain metastases, 28% had squamous histology and 72% had non-squamous histology.

Serious adverse reactions occurred in 58% of patients. YERVOY and nivolumab were discontinued for adverse reactions in 24% of patients and 53% had at least one dose withheld for an adverse reaction. The most frequent (≥2%) serious adverse reactions were pneumonia, diarrhea/colitis, pneumonitis, hepatitis, pulmonary embolism, adrenal insufficiency, and hypophysitis. Fatal adverse reactions occurred in 1.7% of patients; these included events of pneumonitis (4 patients), myocarditis, acute kidney injury, shock, hyperglycemia, multi-system organ failure, and renal failure. The most common (≥20%) adverse reactions were fatigue, rash, decreased appetite, musculoskeletal pain, diarrhea/colitis, dyspnea, cough, hepatitis, nausea, and pruritus.

Tables 1 and 2 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-227.

**Table 1: Adverse Reactions in ≥10% of Patients Receiving YERVOY and Nivolumab - CHECKMATE-227**

Adverse Reaction	YERVOY and Nivolumab (n=576)		Platinum-doublet Chemotherapy (n=570)	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
<b>General</b>				
Fatigue <sup>a</sup>	44	6	42	4.4
Pyrexia	18	0.5	11	0.4
Edema <sup>b</sup>	14	0.2	12	0.5
<b>Skin and Subcutaneous Tissue</b>				
Rash <sup>c</sup>	34	4.7	10	0.4
Pruritus <sup>d</sup>	21	0.5	3.3	0
<b>Metabolism and Nutrition</b>				
Decreased appetite	31	2.3	26	1.4
<b>Musculoskeletal and Connective Tissue</b>				
Musculoskeletal pain <sup>e</sup>	27	1.9	16	0.7
Arthralgia	13	0.9	2.5	0.2
<b>Gastrointestinal</b>				
Diarrhea/colitis <sup>f</sup>	26	3.6	16	0.9
Nausea	21	1.0	42	2.5
Constipation	18	0.3	27	0.5
Vomiting	13	1.0	18	2.3
Abdominal pain <sup>g</sup>	10	0.2	9	0.7
<b>Respiratory, Thoracic, and Mediastinal</b>				
Dyspnea <sup>h</sup>	26	4.3	16	2.1
Cough <sup>i</sup>	23	0.2	13	0
<b>Hepatobiliary</b>				
Hepatitis <sup>j</sup>	21	9	10	1.2
<b>Endocrine</b>				
Hypothyroidism <sup>k</sup>	16	0.5	1.2	0
Hyperthyroidism <sup>l</sup>	10	0	0.5	0
<b>Infections and Infestations</b>				
Pneumonia <sup>m</sup>	13	7	8	4.0
<b>Nervous System</b>				
Headache	11	0.5	6	0

<sup>a</sup> Includes fatigue and asthenia.

<sup>b</sup> Includes eyelid edema, face edema, generalized edema, localized edema, edema, edema peripheral, and periorbital edema.

<sup>c</sup> Includes autoimmune dermatitis, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, dermatitis contact, dermatitis exfoliative, dermatitis psoriasiform, granulomatous dermatitis, rash generalized, drug eruption, dyshidrotic eczema, eczema, exfoliative rash, nodular rash, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, toxic skin eruption.

<sup>d</sup> Includes pruritus and pruritus generalized.

<sup>e</sup> Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, and pain in extremity.

<sup>f</sup> Includes colitis, colitis microscopic, colitis ulcerative, diarrhea, enteritis infectious, enterocolitis, enterocolitis infectious, and enterocolitis viral.

<sup>g</sup> Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.

<sup>h</sup> Includes dyspnea and dyspnea exertional.

<sup>i</sup> Includes cough and productive cough.

<sup>j</sup> Includes alanine aminotransferase increased, aspartate aminotransferase increased, autoimmune hepatitis, blood bilirubin increased, hepatic enzyme increased, hepatic failure, hepatic function abnormal, hepatitis, hepatitis E, hepatocellular injury, hepatotoxicity, hyperbilirubinemia, immune-mediated hepatitis, liver function test abnormal, liver function test increased, transaminases increased.

<sup>k</sup> Includes autoimmune thyroiditis, blood thyroid stimulating hormone increased, hypothyroidism, primary hypothyroidism, thyroiditis, and tri-iodothyronine free decreased.

<sup>l</sup> Contains blood thyroid stimulating hormone decreased, hyperthyroidism, and tri-iodothyronine free increased.

<sup>m</sup> Includes lower respiratory tract infection, lower respiratory tract infection bacterial, lung infection, pneumonia, pneumonia adenoviral, pneumonia aspiration, pneumonia bacterial, pneumonia klebsiella, pneumonia influenza, pneumonia viral, atypical pneumonia, organizing pneumonia.

Other clinically important adverse reactions in CHECKMATE-227 were: *Skin and Subcutaneous Tissue*: urticaria, alopecia, erythema multiforme, vitiligo; *Gastrointestinal*: stomatitis, pancreatitis, gastritis; *Musculoskeletal and Connective Tissue*: arthritis, polymyalgia rheumatica, rhabdomyolysis; *Nervous System*: peripheral neuropathy, autoimmune encephalitis; *Blood and Lymphatic System*: eosinophilia; *Eye Disorders*: blurred vision, uveitis; *Cardiac*: atrial fibrillation, myocarditis.

**Table 2: Laboratory Values Worsening from Baseline<sup>a</sup> Occurring in ≥20% of Patients on YERVOY (ipilimumab) and Nivolumab - CHECKMATE-227**

Laboratory Abnormality	YERVOY and Nivolumab		Platinum-doublet Chemotherapy	
	Grades 1-4 (%)	Grades 3-4 (%)	Grades 1-4 (%)	Grades 3-4 (%)
<b>Hematology</b>				
Anemia	46	3.6	78	14
Lymphopenia	46	5	60	15
<b>Chemistry</b>				
Hyponatremia	41	12	26	4.9
Increased AST	39	5	26	0.4
Increased ALT	36	7	27	0.7
Increased lipase	35	14	14	3.4
Increased alkaline phosphatase	34	3.8	20	0.2
Increased amylase	28	9	18	1.9
Hypocalcemia	28	1.7	17	1.3
Hyperkalemia	27	3.4	22	0.4
Increased creatinine	22	0.9	17	0.2

<sup>a</sup> Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: YERVOY and nivolumab group (range: 494 to 556 patients) and chemotherapy group (range: 469 to 542 patients).

#### First-line Treatment of Metastatic or Recurrent NSCLC: In Combination with Nivolumab and Platinum-Doublet Chemotherapy

The safety of YERVOY in combination with nivolumab and platinum-doublet chemotherapy was evaluated in CHECKMATE-9LA [see *Clinical Studies (14.6) in full Prescribing Information*]. Patients received either YERVOY 1 mg/kg administered every 6 weeks in combination with nivolumab 360 mg administered every 3 weeks and platinum-doublet chemotherapy administered every 3 weeks for 2 cycles; or platinum-doublet chemotherapy administered every 3 weeks for 4 cycles. The median duration of therapy in YERVOY in combination with nivolumab and platinum-doublet chemotherapy was 6 months (range: 1 day to 19 months); 50% of patients received YERVOY and nivolumab for >6 months and 13% of patients received YERVOY and nivolumab for >1 year.

Serious adverse reactions occurred in 57% of patients who were treated with YERVOY in combination with nivolumab and platinum-doublet chemotherapy. The most frequent (>2%) serious adverse reactions were pneumonia, diarrhea, febrile neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis, and respiratory failure. Fatal adverse reactions occurred in 7 (2%) patients, and included hepatic toxicity, acute renal failure, sepsis, pneumonitis, diarrhea with hypokalemia, and massive hemoptysis in the setting of thrombocytopenia.

Study therapy with YERVOY in combination with nivolumab and platinum-doublet chemotherapy was permanently discontinued for adverse reactions in 24% of patients and 56% had at least one treatment withheld for an adverse reaction. The most common (>20%) adverse reactions were fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus.

Tables 3 and 4 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-9LA.

**Table 3: Adverse Reactions in >10% of Patients Receiving YERVOY and Nivolumab and Platinum-Doublet Chemotherapy - CHECKMATE-9LA**

Adverse Reaction	YERVOY and Nivolumab and Platinum-Doublet Chemotherapy (n=358)		Platinum-Doublet Chemotherapy (n=349)	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
<b>General</b>				
Fatigue <sup>a</sup>	49	5	40	4.9
Pyrexia	14	0.6	10	0.6
<b>Musculoskeletal and Connective Tissue</b>				
Musculoskeletal pain <sup>b</sup>	39	4.5	27	2.0
<b>Gastrointestinal</b>				
Nausea	32	1.7	41	0.9
Diarrhea <sup>c</sup>	31	6	18	1.7
Constipation	21	0.6	23	0.6
Vomiting	18	2.0	17	1.4
Abdominal pain <sup>d</sup>	12	0.6	11	0.9
<b>Skin and Subcutaneous Tissue</b>				
Rash <sup>e</sup>	30	4.7	10	0.3
Pruritus <sup>f</sup>	21	0.8	2.9	0
Alopecia	11	0.8	10	0.6
<b>Metabolism and Nutrition</b>				
Decreased appetite	28	2.0	22	1.7
<b>Respiratory, Thoracic and Mediastinal</b>				
Cough <sup>g</sup>	19	0.6	15	0.9
Dyspnea <sup>h</sup>	18	4.7	14	3.2
<b>Endocrine</b>				
Hypothyroidism <sup>i</sup>	19	0.3	3.4	0
<b>Nervous System</b>				
Headache	11	0.6	7	0
Dizziness <sup>j</sup>	11	0.6	6	0

Toxicity was graded per NCI CTCAE v4.

<sup>a</sup> Includes fatigue and asthenia

<sup>b</sup> Includes myalgia, back pain, pain in extremity, musculoskeletal pain, bone pain, flank pain, muscle spasms, musculoskeletal chest pain, musculoskeletal disorder, osteitis, musculoskeletal stiffness, non-cardiac chest pain, arthralgia, arthritis, arthropathy, joint effusion, psoriatic arthropathy, synovitis

<sup>c</sup> Includes colitis, ulcerative colitis, diarrhea, and enterocolitis

<sup>d</sup> Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and gastrointestinal pain

<sup>e</sup> Includes acne, dermatitis, acneiform dermatitis, allergic dermatitis, atopic dermatitis, bullous dermatitis, generalized exfoliative dermatitis, eczema, keratoderma blenorrhagica, palmar-plantar erythrodysesthesia syndrome, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, morbilliform rash, papular rash, pruritic rash, skin exfoliation, skin reaction, skin toxicity, Stevens-Johnson syndrome, urticaria

<sup>f</sup> Includes pruritus and generalized pruritus

<sup>g</sup> Includes cough, productive cough, and upper-airway cough syndrome

<sup>h</sup> Includes dyspnea, dyspnea at rest, and exertional dyspnea

<sup>i</sup> Includes autoimmune thyroiditis, increased blood thyroid stimulating hormone, hypothyroidism, thyroiditis, and decreased free tri-iodothyronine

<sup>j</sup> Includes dizziness, vertigo and positional vertigo

**Table 4: Laboratory Values Worsening from Baseline<sup>a</sup> Occurring in >20% of Patients on YERVOY (ipilimumab) and Nivolumab and Platinum-Doublet Chemotherapy - CHECKMATE-9LA**

Laboratory Abnormality	YERVOY and Nivolumab and Platinum-Doublet Chemotherapy		Platinum-Doublet Chemotherapy	
	Grades 1-4 (%)	Grades 3-4 (%)	Grades 1-4 (%)	Grades 3-4 (%)
<b>Hematology</b>				
Anemia	70	9	74	16
Lymphopenia	41	6	40	11
Neutropenia	40	15	42	15
Leukopenia	36	10	40	9
Thrombocytopenia	23	4.3	24	5
<b>Chemistry</b>				
Hypertglycemia	45	7	42	2.6
Hyponatremia	37	10	27	7
Increased ALT	34	4.3	24	1.2
Increased lipase	31	12	10	2.2
Increased alkaline phosphatase	31	1.2	26	0.3
Increased amylase	30	7	19	1.3
Increased AST	30	3.5	22	0.3
Hypomagnesemia	29	1.2	33	0.6
Hypocalcemia	26	1.4	22	1.8
Increased creatinine	26	1.2	23	0.6
Hyperkalemia	22	1.7	21	2.1

<sup>a</sup> Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: YERVOY and nivolumab and platinum-doublet chemotherapy group (range: 197 to 347 patients) and platinum-doublet chemotherapy group (range: 191 to 335 patients).

#### Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidences of antibodies to other studies or to other products may be misleading.

Of 483 patients evaluable for anti-ipilimumab antibodies in CHECKMATE-227 Part 1, 8.5% were positive for treatment-emergent anti-ipilimumab antibodies. No patients had neutralizing antibodies against ipilimumab. In Part 1 of the same study, of 491 patients evaluable for anti-nivolumab antibodies 36.7% were positive for anti-nivolumab antibodies and 1.4% had neutralizing antibodies against nivolumab.

Of 305 patients evaluable for anti-ipilimumab antibodies in CHECKMATE-9LA, 8% were positive for anti-ipilimumab antibodies and 1.6% were positive for anti-ipilimumab neutralizing antibodies. There was no evidence of increased incidence of infusion reactions to YERVOY in patients with anti-ipilimumab antibodies. Of 308 patients evaluable for anti-nivolumab antibodies in CHECKMATE-9LA, 34% were positive for anti-nivolumab antibodies and 2.6% had neutralizing antibodies against nivolumab.

#### Postmarketing Experience

The following adverse reactions have been identified during postapproval use of YERVOY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Blood and lymphatic system disorders:* hemophagocytic lymphohistiocytosis (HLH)

*Immune System:* graft-versus-host disease, solid organ transplant rejection

*Skin and Subcutaneous Tissue:* Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)

#### USE IN SPECIFIC POPULATIONS

##### Pregnancy

###### Risk Summary

Based on findings from animal studies and its mechanism of action [see *Clinical Pharmacology* (12.1) in full Prescribing Information], YERVOY can cause fetal harm when administered to a pregnant woman. There is insufficient human data for YERVOY exposure in pregnant women. In animal reproduction studies, administration of ipilimumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in higher incidences of abortion, stillbirth, premature delivery (with corresponding lower birth weight), and higher incidences of infant mortality in a dose-related manner [see *Data*]. The effects of ipilimumab are likely to be greater during the second and third trimesters of pregnancy. Human IgG1 is known to cross the placental barrier and ipilimumab is an IgG1; therefore, ipilimumab has the potential to be transmitted from the mother to the developing fetus. Advise pregnant women of the potential risk to a fetus. Report pregnancies to Bristol-Myers Squibb at 1-844-593-7869.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

###### Data

###### Animal Data

In a combined study of embryo-fetal and peri-postnatal development, pregnant cynomolgus monkeys received ipilimumab every 3 weeks from the onset of organogenesis in the first trimester through parturition. No treatment-related adverse effects on reproduction were detected during the first two trimesters of pregnancy. Beginning in the third trimester, administration of ipilimumab at doses resulting in exposures approximately 2.6 to 7.2 times the human exposure at a dose of 3 mg/kg resulted in dose-related increases in abortion, stillbirth, premature delivery (with corresponding lower birth weight), and an increased incidence of infant mortality. In addition, developmental abnormalities were identified in the urogenital system of 2 infant monkeys exposed in utero to 30 mg/kg of ipilimumab (7.2 times the human exposure based on area under the curve at a dose of 3 mg/kg). One female infant monkey had unilateral renal agenesis of the left kidney and ureter, and 1 male infant monkey had an imperforate urethra with associated urinary obstruction and subcutaneous scrotal edema.

Genetically engineered mice heterozygous for CTLA-4 (CTLA-4<sup>+/-</sup>), the target for ipilimumab, appeared healthy and gave birth to healthy CTLA-4<sup>+/-</sup> heterozygous offspring. Mated CTLA-4<sup>+/-</sup> heterozygous mice also produced offspring deficient in CTLA-4 (homozygous negative, CTLA-4<sup>-/-</sup>). The CTLA-4<sup>-/-</sup> homozygous negative offspring appeared healthy at birth, exhibited signs of multiorgan lymphoproliferative disease by 2 weeks of age, and all died by 3 to 4 weeks of age with massive lymphoproliferation and multiorgan tissue destruction.

#### Lactation

##### Risk Summary

There are no data on the presence of YERVOY (ipilimumab) in human milk or its effects on the breastfed child or milk production. In monkeys, ipilimumab was present in milk [see *Data*]. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with YERVOY and for 3 months following the last dose.

##### Data

In monkeys treated at dose levels resulting in exposures 2.6 and 7.2 times higher than those in humans at a 3 mg/kg dose, ipilimumab was present in milk at concentrations of 0.1 mcg/mL and 0.4 mcg/mL, representing a ratio of up to 0.3% of the steady-state serum concentration of the drug.

#### Females and Males of Reproductive Potential

##### Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating YERVOY [see *Use in Specific Populations—Pregnancy*].

##### Contraception

YERVOY can cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations—Pregnancy*]. Advise females of reproductive potential to use effective contraception during treatment with YERVOY and for 3 months following the last dose.

##### Pediatric Use

The safety and effectiveness of OPDIVO (nivolumab) and YERVOY have not been established in pediatric patients less than 18 years old with NSCLC.

##### Geriatric Use

Of the 576 patients randomized to YERVOY 1 mg/kg every 6 weeks with nivolumab 3 mg/kg every 2 weeks in CHECKMATE-227 (NSCLC), 48% were 65 years or older and 10% were 75 years or older. No overall difference in safety was reported between older patients and younger patients; however, there was a higher discontinuation rate due to adverse reactions in patients aged 75 years or older (29%) relative to all patients who received YERVOY with nivolumab (18%). Of the 396 patients in the primary efficacy population (PD-L1  $\geq 1\%$ ) randomized to YERVOY 1 mg/kg every 6 weeks with nivolumab 3 mg/kg every 2 weeks with in CHECKMATE-227, the hazard ratio for overall survival was 0.70 (95% CI: 0.55, 0.89) in the 199 patients younger than 65 years compared to 0.91 (95% CI: 0.72, 1.15) in the 197 patients 65 years or older [see *Clinical Studies* (14.6) in full Prescribing Information].

Of the 361 patients randomized to YERVOY 1 mg/kg every 6 weeks in combination with nivolumab 360 mg every 3 weeks and platinum-doublet chemotherapy every 3 weeks (for 2 cycles) in CHECKMATE-9LA (NSCLC), 51% were 65 years or older and 10% were 75 years or older. No overall difference in safety was reported between older patients and younger patients; however, there was a higher discontinuation rate due to adverse reactions in patients aged 75 years or older (43%) relative to all patients who received YERVOY with nivolumab and chemotherapy (24%). For patients aged 75 years or older who received chemotherapy only, the discontinuation rate due to adverse reactions was 16% relative to all patients who had a discontinuation rate of 13%. Based on an updated analysis for overall survival, of the 361 patients randomized to YERVOY in combination with nivolumab and platinum-doublet chemotherapy in CHECKMATE-9LA, the hazard ratio for overall survival was 0.61 (95% CI: 0.47, 0.80) in the 176 patients younger than 65 years compared to 0.73 (95% CI: 0.56, 0.95) in the 185 patients 65 years or older.

#### PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

##### Immune-Mediated Adverse Reactions

Advise patients that YERVOY can cause immune-mediated adverse reactions including the following [see *Warnings and Precautions*]:

- Immune-Mediated Diarrhea or Colitis: Advise patients to contact their healthcare provider immediately for signs or symptoms of diarrhea or colitis.
- Immune-Mediated Hepatitis: Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatitis.
- Immune-Mediated Dermatologic Adverse Reactions: Advise patients to contact their healthcare provider immediately if they develop a new rash.
- Immune-Mediated Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypophysitis, adrenal insufficiency, hypothyroidism, hyperthyroidism, and diabetes mellitus
- Immune-Mediated Pneumonitis: Advise patients to contact their healthcare provider immediately for any new or worsening symptoms of pneumonitis.
- Immune-Mediated Nephritis with Renal Dysfunction: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis.

##### Infusion-Related Reactions

Advise patients who are receiving YERVOY of the potential risk of an infusion-related reaction [see *Warnings and Precautions*].

##### Embryo-Fetal Toxicity

- Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see *Warnings and Precautions* and *Use in Specific Populations*].
- Advise females of reproductive potential to use effective contraception during treatment with YERVOY and for 3 months after the last dose [see *Use in Specific Populations*].
- Advise patients who may have been exposed to YERVOY during pregnancy to contact Bristol-Myers Squibb at 1-844-593-7869 [see *Use in Specific Populations*].

#### Lactation

- Advise women not to breastfeed during treatment with YERVOY and for 3 months after the last dose [see *Use in Specific Populations*].

Manufactured by:  
Bristol-Myers Squibb Company  
Princeton, NJ 08543 USA  
U.S. License No. 1713

Revised: November 2020

7356US2004270-01-01 11/20



# About the Expert



**Martin Dietrich, MD, PhD**  
Medical Oncologist  
Florida Cancer Specialists & Research Institute  
Orlando, FL

Martin Dietrich, MD, PhD, is Board-certified in internal medicine and medical oncology. In his clinical practice, he addresses all aspects of hematologic and oncologic care, with a special research interest in the treatment of lung and breast cancer, and genetic evaluation and counseling of somatic and hereditary syndromes. He also holds a faculty appointment at the University of Central Florida in Orlando as an assistant professor of internal medicine.

Dr Dietrich holds doctorates in cancer biology from the German Cancer Research Center, Heidelberg, Germany, and in molecular genetics from the University of Texas Southwestern Graduate School. He completed his fellowships in Hematology/Oncology in the physician-scientist training track at the University of Texas Southwestern Track as a T32 scholar of the National Cancer Institute. His expertise in molecular genetics translates into a clinical philosophy of matching tailored therapies to each patient's individual tumor biology.

A principal investigator in numerous precision medicine-based trials, Dr Dietrich is focusing on the clinical development of novel anti-cancer agents. He also conducts clinical-translation research in genetic testing modalities, "liquid" biopsies and the optimization of diagnostic findings.

As a fellow of the American College of Physicians (FACP) and a Board-certified internist, Dr. Dietrich believes in a comprehensive approach to his patients' medical care.

He is a member of the American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC), American Association for Cancer Research (AACR), American Society of Hematology (ASH), and the European Society of Medical Oncology (ESMO).

He has authored numerous peer-reviewed articles published in *Cancer Cell*, *Cancer Research*, *Blood*, *Oncogene*, *Journal of Thoracic Oncology*, *Journal of Oncology Practice* and *JAMA Oncology*, as well as book chapters and abstracts. He has lectured extensively both nationally and internationally on the topics of molecular genetics, immunotherapies, and thoracic malignancies.

Dr Dietrich was paid to share his perspective in this interview. He has also served as a clinical investigator and a scientific advisor for Bristol-Myers Squibb Company.



© 2021 Bristol-Myers Squibb Company. All rights reserved. Printed in USA.  
OPDIVO® and YERYOY® are trademarks of Bristol-Myers Squibb Company.

7356US2004003-01-01 01/21